Erdilyi, D.J., Kamory, E., Csokay, B., et al. (2008) Synergistic Interaction of ABCB1 and ABCG2 Polymorphisms Predicts the Prevalence of Toxicencephalopathy during Anticancer Chemotherapy. The Pharmacogenomics Journal, 8, 321-327.
https://doi.org/10.1038/sj.tpj.6500480

has been cited by the following article:

• TITLE: Chemotherapy-Induced Cognitive Decline: Moving from the Mechanistic Debate towards Prevention and Treatment—A Clinical Review

  AUTHORS: Roi Tschernichovsky, Lauren Philp, Annekathryn Goodman

  KEYWORDS: Chemotherapy, Cognitive Decline, Cognitive Impairment, Chemo-Brain, Chemo-Fog, Cancer Survivorship, Quality of Life

  JOURNAL NAME: Journal of Cancer Therapy, Vol.10 No.12, December 24, 2019

  ABSTRACT: Patients receiving chemotherapy have reported cognitive challenges including short-term memory loss and reduced executive functioning. While cognitive decline can be multifactorial and related to aging, depression, surgery, and other medications, there has been a steadily increasing body of knowledge showing a significant association between cognitive decline and chemotherapy administration. This clinical review summarizes patient-reported cognitive changes, support from neuroimaging and neuropsychological testing. The mechanism of action of and patient susceptibilities to cognitive decline are reviewed. Current behavioral and pharmacologic interventions are discussed. There is a need to identify patients at risk for developing chemotherapy induced cognitive decline andtoscreen for early signs of cognitive deterioration. The risk of cognitive dysfunction and possible interventions should be included in the informed consent discussion with patients who are undergoing cytotoxic treatments.